Literature DB >> 19940524

TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients.

Maria Lina Tornesello1, Bennon Biryahwaho, Robert Downing, Angelo Hatzakis, Elvio Alessi, Marco Cusini, Vincenzo Ruocco, Edward Katongole-Mbidde, Luigi Buonaguro, Franco M Buonaguro.   

Abstract

OBJECTIVES: Several studies have examined the association of codon 72 polymorphism of the TP53 gene, encoding either arginine or proline, in several tumor types but none have investigated its role in Kaposi's sarcoma (KS) development.
METHODS: In this prevalent case-control study, 67 cutaneous lesions of classic, iatrogenic, endemic as well as epidemic KS from African (n = 22) and Caucasian (n = 45) patients, and blood samples from 150 healthy controls (n = 57 African, n = 93 Caucasian) have been analyzed for arginine and proline allele distribution.
RESULTS: Among African cases the proline homozygous, heterozygous and arginine homozygous genotype frequencies were 50.0, 31.8 and 18.2%, respectively, and among controls 54.4, 40.3, and 5.3%, respectively (p = 0.1872). Conversely, among Caucasian cases genotype distributions were 6.7, 55.6, and 37.8%, and among controls 7.5, 34.4, and 58.1%, respectively (p = 0.0567). No significant differences in arginine and proline allele distribution were observed when the cases were stratified by HIV status/tumor type.
CONCLUSIONS: The results obtained in this study suggest that p53 polymorphism at codon 72 does not represent a risk factor for the development of all forms of KS, either among African or among Caucasian populations. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19940524     DOI: 10.1159/000260905

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

1.  Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.

Authors:  Fengchun Ye; Ali Abdul Lattif; Jianping Xie; Aaron Weinberg; Shoujiang Gao
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

2.  Association between p53 codon 72 polymorphism and sarcoma risk among Caucasians.

Authors:  Zhengqi Chang; Xiuchun Yu
Journal:  Tumour Biol       Date:  2014-01-22

3.  The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.

Authors:  Xu Cai; Ming Yang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-29       Impact factor: 4.553

4.  TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.

Authors:  Rym Abderrahmane; Lotfi Louhibi; Fatima Zohra Moghtit; Amina Boubekeur; Khedidja Benseddik; Abdellah Boudjema; Fouzia Benrrahal; Meriem Aberkane; Mostefa Fodil; Nadhira Saidi-Mehtar
Journal:  Pathol Oncol Res       Date:  2014-12-24       Impact factor: 3.201

5.  Polymorphisms in promoter sequences of MDM2, p53, and p16 genes in normal Japanese individuals.

Authors:  Yasuhito Ohsaka; Hoyoku Nishino
Journal:  Genet Mol Biol       Date:  2010-12-01       Impact factor: 1.771

6.  TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients.

Authors:  Valeria Di Vuolo; Luigi Buonaguro; Francesco Izzo; Simona Losito; Gerardo Botti; Franco M Buonaguro; Maria Lina Tornesello
Journal:  Infect Agent Cancer       Date:  2011-08-15       Impact factor: 2.965

Review 7.  Clonality, Mutation and Kaposi Sarcoma: A Systematic Review.

Authors:  Blanca Iciar Indave Ruiz; Subasri Armon; Reiko Watanabe; Lesley Uttley; Valerie A White; Alexander J Lazar; Ian A Cree
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

8.  Structural proteins of Kaposi's sarcoma-associated herpesvirus antagonize p53-mediated apoptosis.

Authors:  P Chudasama; A Konrad; R Jochmann; B Lausen; P Holz; E Naschberger; F Neipel; N Britzen-Laurent; M Stürzl
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

9.  Trends in Kaposi's Sarcoma in Miami Beach from 1987 to 2007.

Authors:  Simon B Zeichner; Ana L Ruiz; Gabriel P Suciu; Rachel Lerner Zeichner; Estelamari Rodriguez
Journal:  ISRN Oncol       Date:  2012-12-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.